Clinical Trial News and Research

RSS

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

itm FlowMedical GmbH announced the start of OPEN-188 clinical trial. It will compare itm Rhenium-PTA, a therapy for the prevention of restenosis in peripheral vessels, to a regular PTA, the standard therapy for the treatment of PAOD.

23 Aug 2011

Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs

TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Aptiv Solutions acquires Medical Device Consultants

Aptiv Solutions announced today the acquisition of Medical Device Consultants, Inc. (MDCI), a provider of expert medical device consulting and clinical trial management and execution.

23 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Living Cell Technologies xenoimplants first patients in Argentina trial

Living Cell Technologies Limited has implanted the first two patients taking part in a Phase II DIABECELL® clinical trial in Buenos Aires, Argentina.

22 Aug 2011

Scientists discover key defense mechanism against C. difficile infection

Researchers have discovered a key mechanism used by intestinal cells to defend themselves against one of the world's most common hospital-acquired bacterial infections - a mechanism they think they can exploit to produce a therapy to protect against the effects of the antibiotic-resistant bacteria.

22 Aug 2011

Wistar Institute, Graham Cancer Center enter research collaboration

Christiana Care Health System's Helen F. Graham Cancer Center and The Wistar Institute, an international leader in biomedical research, have entered into an historic partnership to collaborate on translational cancer research with the aim of bringing the latest discoveries in cancer research to cancer patients in the community.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

AMRI today announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.

19 Aug 2011

High blood phosphate levels can set CKD patients on a rapid path to kidney failure

High blood phosphate levels can set chronic kidney disease (CKD) patients on a rapid path to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

19 Aug 2011

Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients

Antibiotics can help ward off serious bacterial infections in kidney disease patients who use tubes called catheters for their dialysis treatments. But if antibiotics are used too often, "super bugs" may crop up that are resistant to the drugs.

19 Aug 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

Gene Security Network announces commercial launch of non-invasive prenatal test

Gene Security Network Inc. (GSN) today announced the commercial launch of its first non-invasive prenatal test powered by the company's proprietary bioinformatics technology, Parental Support™.

18 Aug 2011

Scientists artificially grow brain cells from Parkinson's patients to find treatment

The UK's population is ageing and with it comes an increased risk of developing age-related diseases such as Parkinson's. About 70% of dopamine producing brain cells will have been lost by the time a sufferer visits the doctor, with symptoms that include difficulties with movement and a resting tremor. A progressive neurodegenerative disease, Parkinson's affects about 120,000 people in the UK.

18 Aug 2011

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

Clinical Trial News and Research

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

BioLineRx second quarter net loss decreases to NIS 16.4 million

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs

Spinifex secures AU$6.25 million in expanded Series B funding

Aptiv Solutions acquires Medical Device Consultants

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Living Cell Technologies xenoimplants first patients in Argentina trial

Scientists discover key defense mechanism against C. difficile infection

Wistar Institute, Graham Cancer Center enter research collaboration

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

High blood phosphate levels can set CKD patients on a rapid path to kidney failure

Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

Gene Security Network announces commercial launch of non-invasive prenatal test

Scientists artificially grow brain cells from Parkinson's patients to find treatment

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer